CTOs on the Move

GlobalTox

www.globaltox.ca

 
GlobalTox is a Guelph, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.globaltox.ca
  • 255 Speedvale Ave W
    Guelph, ON CAN N1H 1C5
  • Phone: 519.766.1000

Executives

Name Title Contact Details

Similar Companies

Sun protection zone

Sun protection zone is a Cypress, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Delaware Physicians Care

Delaware Physicians Care is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.

JAXJOX

JAXJOX is a global fitness company revolutionizing the health and wellness industry through technology-enabled, connected at-home exercise equipment.

StemCells

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.